Dordaviprone Maintenance After Allogeneic HCT for High-Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm [0.03%]
同种异体造血干细胞移植后多拉维普隆维持治疗高危急性髓系白血病和骨髓增生性肿瘤
Vijaya Raj Bhatt,Christopher S Wichman,Alyssa Bouska et al.
Vijaya Raj Bhatt et al.
Dordaviprone is a first-in-class small-molecule imipridone. In preclinical studies, it is active against leukemia cells harboring a TP53 mutation or complex karyotype and leukemia stem cells while sparing normal bone marrow cells. This stud...
Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma [0.03%]
接受西妥昔单抗自体T细胞治疗复发/难治性多发性骨髓瘤患者的早期治疗失败
Kenneth J C Lim,Shaji Kumar,Ricardo Parrondo et al.
Kenneth J C Lim et al.
Ciltacabtagene autoleucel (cilta-cel) has demonstrated excellent efficacy and long-term disease control in patients with relapsed/refractory multiple myeloma (RRMM). However, a proportion of patients experience early treatment failures. We ...
Impact of Atrial Fibrillation on the Risk of Thrombosis and Bleeding for Patients With Polycythemia Vera and Essential Thrombocytosis in the Real World [0.03%]
真实世界中真性红细胞增多症和原发性血小板增多症患者房颤对血栓和出血风险的影响
Rodrigo Ortega Perez,Luis Manuel Domínguez Rodríguez,Francisca Ferrer-Marín et al.
Rodrigo Ortega Perez et al.
Mosaic Chromosomal Alterations Identify Ultra-High Risk Clonal Hematopoiesis in Patients With Lymphoma Undergoing Intensive Chemotherapy [0.03%]
复杂的染色体改变可判断接受强化化疗的淋巴瘤患者中极高的克隆细胞血液病风险
Mathias Æ Heldbo,Kirstine Ostenfeld Larsen,Nikolaj Juul Nitschke et al.
Mathias Æ Heldbo et al.
A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis [0.03%]
中国多中心国家轻链型淀粉样变性登记研究：真实世界诊断、治疗和预后的见解
Jing Li,Chenqi Yu,Jinghua Wang et al.
Jing Li et al.
This national, multicenter, retrospective study analyzed 1070 patients with newly diagnosed systemic light-chain (AL) amyloidosis in China (2008-2025). Findings reveal increasing annual diagnoses and a marked shift in first-line therapy fro...
Extended Cancer Spectrum in Adults With Telomere Biology Disorders: Insights From a 113-Patient Single-Center Cohort [0.03%]
telomeropathy成人患者肿瘤谱的扩大：来自单中心113例患者的启示
Madeline A Franke,Terra L Lasho,Christy M Finke et al.
Madeline A Franke et al.
Limited Survival Benefit and High Healthcare Utilization With AML-Directed Therapy in Older Patients With TP53-Mutated Acute Myeloid Leukemia [0.03%]
TP53突变型急性髓系白血病老年患者的治疗效果有限且医疗利用率高
Tina Y Zhang,Alex Y Ge,Lloyd Hutchinson et al.
Tina Y Zhang et al.
When Cure Meets Susceptibility: APOL1-Associated Kidney Injury After Gene Therapy for Sickle Cell Disease [0.03%]
基因治疗后 sickle cell disease 患者出现 APOL1 相关性肾损伤的预防与对策
Evelyn Gartstein,Lauren McNaughton,O N Ray Bignall et al.
Evelyn Gartstein et al.
Long-Term Outcomes of Mayo Stage IIIb AL Amyloidosis Treated With Daratumumab-Based Frontline Therapy [0.03%]
达雷妥尤单抗为基础的一线疗法治疗马约分期IIIb期AL淀粉样变性的长期疗效分析
Simon Zhen,Sorina Nicoleta Bandelita,Divaya Bhutani et al.
Simon Zhen et al.
of baseline characteristics, treatment regimens, hematologic and cardiac responses, and survival outcomes among 51 patients with Mayo stage IIIb AL amyloidosis treated with daratumumab-based frontline therapy. ...